Clinical Trial Update: EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes following a CD45 antibody in patients with EBV-positive nasopharyngeal carcinoma; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Nasopharyngeal Carcinoma

Drugs mentioned

• CD45 antibody
• EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Nasopharyngeal Cancer, EBV Infections | Phase 1 | Status: COMPLETED